Lisa Astor

Patients with hormone receptor–positive, HER2-negative metastatic breast cancer derived benefit with sacituzumab govitecan regardless of Trop-2 expression.

Following treatment with rusfertide, patients with polycythemia vera were able to significantly reduce their need for blood draws.

Phase 3 findings showed that panitumumab plus mFOLFOX significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer.

Ovarian clear cell carcinoma is a rare histological type of epithelial ovarian cancer that is typically resistant to chemotherapy and is historically associated with poor prognosis for patients.

Panitumumab with mFOLFOX demonstrated a clinical benefit for patients with left-sided RAS wild-type metastatic colorectal cancer in the PARADIGM trial (NCT02394795).

The combination of PARP inhibition and androgen receptor targeted therapy was found to be tolerable in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.

A phase 2 study reported clinical efficacy from the use of frontline belzutifan in patients with Von-Hippel Lindau (VHL).

Lifileucel produced durable responses in advanced melanoma that was previously treated an an immunotherapy agent.

Significant differences were seen between Hispanic and non-Hispanic white patients with hematological malignancies in Texas in terms of the age of diagnosis and long-term survival outcomes.

Chemotherapy administered within 3 months of a diagnosis of coronavirus disease 2019 (COVID-19) increased the risk of death in patients with thoracic cancer, according to findings from the global TERAVOLT Consortium registry.

The FDA has granted a fast track designation to the KRAS inhibitor AMG 510 for the treatment of patients who received prior treatment with KRAS G12C-mutated NSCLC.

According to the MATCH trial, about a quarter of pediatric patients with cancer were able to be screened for targetable alterations in their tumor and directed to a treatment targeting that alteration.

In a presentation during the 16th Annual Winter Lung Conference™, Gregory J. Riely, MD, PhD, discussed the spectrum of activity of many of these FDA-approved EGFR TKIs.

A large pivotal phase III trial has been initiated to evaluate the potential for the first-line combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in comparison with standard-of-care sorafenib (Nexavar) for patients with advanced hepatocellular carcinoma (HCC).

Delayed treatment with chemotherapy of more than 30 days after surgery for patients with triple-negative breast cancer (TNBC) is associated with worse survival rates and outcomes than those who receive adjuvant chemotherapy within 30 days of their procedure, according to findings from a retrospective study performed in Peru presented at the 2018 San Antonio Breast Cancer Symposium (SABCS).

Patients with head and neck cancer (HNC) who tracked their symptoms using the CYCORE (CYberinfrastructure for COmparative Effectiveness REsearch) system’s mobile and sensor technology experienced reduced symptom severity compared with those who received standard care, according to results of a large randomized trial.

Neoadjuvant treatment with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) demonstrated almost a tripling in objective response rate (ORR) compared with the PD-1 inhibitor alone but at the cost of significant added grade 3 adverse events (AEs) for patients with high-risk resectable melanoma, according to a small study presented at the 2017 SITC Annual Meeting.